Editorial & Opinion
Sodium-Glucose Co-Transporter-2 Inhibitor Therapy During Anthracycline Treatment: Is There a Role for Cardioprotection?
| العنوان: | Sodium-Glucose Co-Transporter-2 Inhibitor Therapy During Anthracycline Treatment: Is There a Role for Cardioprotection? |
|---|---|
| المؤلفون: | Khouri MG; Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: michel.khouri@duke.edu., Greene SJ; Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA. |
| المصدر: | JACC. Heart failure [JACC Heart Fail] 2022 Aug; Vol. 10 (8), pp. 568-570. Date of Electronic Publication: 2022 Jul 06. |
| نوع المنشور: | Editorial; Comment |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 101598241 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-1787 (Electronic) Linking ISSN: 22131779 NLM ISO Abbreviation: JACC Heart Fail Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, NY : Elsevier, [2013]- |
| مواضيع طبية MeSH: | Heart Failure*/drug therapy , Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use , Symporters*, Anthracyclines/adverse effects ; Glucose ; Humans ; Sodium |
| مستخلص: | Competing Interests: Funding Support and Author Disclosures Dr Khouri has received research support from Pfizer and Alnylam Pharmaceuticals; has served on advisory boards for Pfizer, Eidos Therapeutics, and Alnylam Pharmaceuticals; and has received speaker fees from Alnylam Pharmaceuticals. Dr Greene has received research support from the Duke University Department of Medicine Chair’s Research Award, American Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; has received speaker fees from Boehringer Ingelheim; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, PharmaIN, Roche Diagnostics, Sanofi, Tricog Health, Urovant Pharmaceuticals, and Vifor. |
| التعليقات: | Comment on: JACC Heart Fail. 2022 Aug;10(8):559-567. (PMID: 35902159) |
| فهرسة مساهمة: | Keywords: SGLT2 inhibitors; anthracyclines; cardiotoxicity; chemotherapy; heart failure |
| المشرفين على المادة: | 0 (Anthracyclines) 0 (Sodium-Glucose Transporter 2 Inhibitors) 0 (Symporters) 9NEZ333N27 (Sodium) IY9XDZ35W2 (Glucose) |
| تواريخ الأحداث: | Date Created: 20220728 Date Completed: 20220801 Latest Revision: 20220918 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1016/j.jchf.2022.04.014 |
| PMID: | 35902160 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2213-1787 |
|---|---|
| DOI: | 10.1016/j.jchf.2022.04.014 |